|
TFG Experience
Barry founded The Frankel Group in March of 1993. Following nearly 20 years in the life science industry, Barry saw an opportunity to pull together a team of experienced professionals from suppliers, providers, banking and consulting to provide creative yet actionable strategic solutions to the pharmaceutical, biotechnology and device/diagnostics industries.
Since the founding of TFG, Barry has advised and managed a diverse range of engagements, including business strategies and franchise development strategies; the identification and valuation of acquisition, licensing and alliance candidates; R&D portfolio planning and technology platform assessments; market entry and commercialization strategies; and forward integration strategies employing internal assets, channel intermediaries and disease management initiatives. Clients have spanned multinational pharmaceutical companies, biotechnology and startup pharmaceutical organizations, device and diagnostic firms, industry intermediaries including CROs and CSOs, technology companies seeking to leverage their product platforms into life science, and industry trade and patient advocacy organizations.
Recent assignments have included: (1) a strategy to leverage drug delivery technology upstream in lead optimization to create a parallel development pathway for a multinational pharmaceutical company; (2) a global market entry strategy for a major multisource pharmaceutical company into the emerging generic biologics market; (3) a business migration strategy in multisource and drug delivery enhanced products for a specialty generics company; (4) account targeting, marketing strategy development and sales force planning for a US multisource division of a global pharmaceutical company; (5) a series of strategic advisory efforts for a public biotechnology company in determining their business strategy, acquisition identification and assessment, and commercialization organization development; and (6) a reorganization strategy for an industry trade association to better address evolving member product technologies and external global regulations. In addition, Barry has led TFG's expansion into the venture capital area, holding an asset management advisory role with equity4life, AG, a Switzerland based venture capital firm focused on investments in biotechnology, medical device/diagnostic and health care service startups on a global basis. With the movement into a successful liquidation phase of this fund, Barry and his partners are forming a new venture investment vehicle, BioDevelopment Ventures, LP. BioDevelopment Ventures is designed to further leverage the expertise of TFG in R&D planning, licensing/acquisitions and product commercialization given its intention to apply private equity and internal development expertise to the acquisition, Phase I - II development, and industry exit of promising early-stage pharmaceutical product candidates.
Pre-TFG Experience
Prior to TFG, Barry was President of SJ Weinstein Associates, a health care marketing strategy and advertising firm, where he formulated marketing and communications strategies for some of the leading life science companies. His earlier experience included strategic planning for Pfizer Pharmaceuticals, as well as senior marketing positions at Pfizer in the anti-infective, multisource pharmaceutical and diagnostic markets. In addition, Barry was an Investment Research Officer for life science investments at Citibank.
Education
Barry holds a Masters in Business Administration with Distinction from The Wharton School of The University of Pennsylvania, and a Bachelors of Science Summa Cum Laude in Engineering from Rutgers University.
| 